Dataset opportunity
Markennovy — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Markennovy, usable for Diagnostic AI and Computer Vision.
Score
62.6
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
Global AI in ophthalmology market = $209.23 million in 2024, CAGR 36.79% (source: Grand View Research). [1]
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-06-16
J&J commits $1B to expand contact lens production in Florida
manufacturingdive.com ↗ - 📰press2026-06-16
J&J commits $1B to expand contact lens production in Florida
medtechdive.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Markennovy holds a substantial Medical Imaging Dataset derived from its industrial-scale contact lens manufacturing operations. This dataset uniquely combines ocular Image data with corresponding medical_records, including prescriptions and precise ocular measurements, making it exceptionally well-suited for training and validating Diagnostic AI models for a range of ophthalmological conditions.
The global AI in Ophthalmology market was valued at $209.23 million in 2024 and is projected to grow at an explosive 36.79% CAGR. [1] Despite access complexities due to its sensitive nature and deep integration with proprietary processes, the dataset's rarity and direct applicability to this high-growth market represent a significant and valuable opportunity for AI developers seeking a competitive edge. ⚠ Diligence (valuable data, access to negotiate): Subsidiary of Euclid Vision Group (PE-backed by Kohlberg & Company); Contains sensitive medical/health data (prescriptions and ocular measurements); Data is deeply integrated into proprietary manufacturing processes · corporate: subsidiary of Euclid Vision Group.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
Collectively, this evidence indicates Markennovy possesses a vast, proprietary repository of biometric eye data linked to corresponding lens geometries. This dataset is a foundational asset for companies building diagnostic AI to address common conditions like astigmatism and myopia. In a global AI in ophthalmology market projected to grow at over 36% annually, this unique data of significant scale provides a critical competitive advantage for training and validating next-generation imaging models.
See dimension details ↓- Dataset Specificity78
dominant 'medical_records', sector healthcare, 2 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity70
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume68
3 evidence hits, explicit data-volume mention
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
periodic
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
Buyer demand is exceptionally high, driven by the AI in Ophthalmology market's rapid expansion at a sourced **CAGR** of 36.79%, creating urgent demand for high-quality, industrial-scale training data. [1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, subsidiary of Euclid Vision Group
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence50
subsidiary of Euclid Vision Group
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 data-appetite signals (0 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 2 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit92
✓ good target — Markennovy is a strong fit, as its core business is manufacturing custom-fit contact lenses, which generates a significant amount of proprietary production and patient parameter data as a by-product without evidence of it being sold. Issues: The company is a subsidiary of a larger global group, Euclid Vision Group, which might complicate data ownership and decision-making. [1, 9]
- Deep Qualification80
✓ pass — Mark'ennovy is a manufacturer of custom contact lenses, not a data seller; it holds significant, dormant biometric and prescription data as a byproduct of its core business. This data is highly sensitive under GDPR, originating from patients via eye care professionals, making its ownership mixed and
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Industrial data
This is evidence of highly detailed manufacturing parameters for bespoke lenses, valuable for AI models that must connect diagnostic outputs to the final physical product.
Medical records / imaging
This indicates the data contains patient-specific medical conditions and is curated by opticians, directly linking biometric inputs to clinical diagnoses and customized lens solutions.
Data-volume signal
This evidence strongly suggests the existence of a massive, proprietary repository of biometric data and corresponding lens geometries, indicating a dataset of significant scale and diversity.
Coverage
Scanned sources
Deliverable
Premium dataset report
Markennovy Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in ophthalmology market = $209.23 million in 2024, CAGR 36.79% (source: Grand View Research). [1]. Investment score 62.6/100 (confidence 0.49). Recommended action: Data Sharing Agreement.